Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 TreatmentsGlobeNewsWire • 03/25/26
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline StrengthGlobeNewsWire • 03/25/26
Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites RallyBenzinga • 03/18/26
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical StudyGlobeNewsWire • 03/18/26
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma PatientsGlobeNewsWire • 03/18/26
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial ResultsGlobeNewsWire • 02/24/26
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol CandidateGlobeNewsWire • 12/23/25
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/12/25
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in CancerGlobeNewsWire • 11/04/25
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial OfficerGlobeNewsWire • 10/27/25
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development SummitGlobeNewsWire • 10/15/25
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society ConferenceGlobeNewsWire • 09/29/25
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS ResultsGlobeNewsWire • 09/03/25
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)GlobeNewsWire • 09/03/25
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent PainGlobeNewsWire • 08/25/25
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/13/25
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13GlobeNewsWire • 08/11/25
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve AssetGlobeNewsWire • 08/04/25
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and DepressionGlobeNewsWire • 08/01/25